Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-08-09

AUTHORS

Maryam Karimi Khaledi, Katie J. Suda, Chasity M. Shelton

ABSTRACT

Case The objective of this case report is to report the development of tardive dyskinesia in an African-American adolescent male after short-term treatment with metoclopramide 10 mg orally three times daily secondary to delayed gastric emptying. The patient developed symptoms of tardive dyskinesia after 2 days of therapy with metoclopramide. Metoclopramide was discontinued and diphenhydramine 50 mg was initially administered intravenously followed with 25 mg orally every 4 hours as needed. While there are case reports of drug-induced tardive dyskinesia after intravenous administration of metoclopramide, this is to our knowledge the first report of tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent. Conclusion Awareness of the risk of development of this adverse effect even with short-term treatment with metoclopramide and in younger patients is important. More... »

PAGES

822-824

References to SciGraph publications

  • 1981-08. A method for estimating the probability of adverse drug reactions in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s11096-012-9685-4

    DOI

    http://dx.doi.org/10.1007/s11096-012-9685-4

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1024100946

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/22875741


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Oral", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adolescent", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Age Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antiemetics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diphenhydramine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Administration Schedule", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Substitution", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Metoclopramide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Movement Disorders", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 340, 38163, Memphis, TN, USA", 
              "id": "http://www.grid.ac/institutes/grid.267301.1", 
              "name": [
                "Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 340, 38163, Memphis, TN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Karimi Khaledi", 
            "givenName": "Maryam", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 340, 38163, Memphis, TN, USA", 
              "id": "http://www.grid.ac/institutes/grid.267301.1", 
              "name": [
                "Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 340, 38163, Memphis, TN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Suda", 
            "givenName": "Katie J.", 
            "id": "sg:person.0601042140.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601042140.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 343, 38163, Memphis, TN, USA", 
              "id": "http://www.grid.ac/institutes/grid.267301.1", 
              "name": [
                "Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 343, 38163, Memphis, TN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shelton", 
            "givenName": "Chasity M.", 
            "id": "sg:person.0715544021.50", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715544021.50"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/clpt.1981.154", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040267576", 
              "https://doi.org/10.1038/clpt.1981.154"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2012-08-09", 
        "datePublishedReg": "2012-08-09", 
        "description": "Case The objective of this case report is to report the development of tardive dyskinesia in an African-American adolescent male after short-term treatment with metoclopramide 10\u00a0mg orally three times daily secondary to delayed gastric emptying. The patient developed symptoms of tardive dyskinesia after 2\u00a0days of therapy with metoclopramide. Metoclopramide was discontinued and diphenhydramine 50\u00a0mg was initially administered intravenously followed with 25\u00a0mg orally every 4\u00a0hours as needed. While there are case reports of drug-induced tardive dyskinesia after intravenous administration of metoclopramide, this is to our knowledge the first report of tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent. Conclusion Awareness of the risk of development of this adverse effect even with short-term treatment with metoclopramide and in younger patients is important.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s11096-012-9685-4", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1044817", 
            "issn": [
              "2210-7703", 
              "2210-7711"
            ], 
            "name": "International Journal of Clinical Pharmacy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "34"
          }
        ], 
        "keywords": [
          "short-term treatment", 
          "oral metoclopramide", 
          "case report", 
          "days of therapy", 
          "risk of development", 
          "metoclopramide 10", 
          "younger patients", 
          "Conclusion Awareness", 
          "intravenous administration", 
          "metoclopramide", 
          "adverse effects", 
          "adolescent males", 
          "patients", 
          "treatment", 
          "African American adolescent males", 
          "report", 
          "adolescents", 
          "first report", 
          "therapy", 
          "symptoms", 
          "administration", 
          "risk", 
          "males", 
          "days", 
          "hours", 
          "development", 
          "cases", 
          "awareness", 
          "effect", 
          "objective", 
          "knowledge", 
          "time"
        ], 
        "name": "Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent", 
        "pagination": "822-824", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1024100946"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s11096-012-9685-4"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "22875741"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s11096-012-9685-4", 
          "https://app.dimensions.ai/details/publication/pub.1024100946"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-12-01T19:26", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_576.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s11096-012-9685-4"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11096-012-9685-4'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11096-012-9685-4'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11096-012-9685-4'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11096-012-9685-4'


     

    This table displays all metadata directly associated to this object as RDF triples.

    165 TRIPLES      22 PREDICATES      72 URIs      63 LITERALS      20 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s11096-012-9685-4 schema:about N3e5ec56a2589450dbd4b4fb1c8ddc5b9
    2 N482bed2db8e4480aa6b5610b1faa9b33
    3 N4c92672c59e34e559b79a764fa28a5e4
    4 N5bdb298e89804acd98d4ba11098c4b05
    5 N640a0d24afc74a248d850eb39e459318
    6 N65397430d53f479480831050017bd91d
    7 N71ee21f9499a4f29b16cee2a4bfed5a4
    8 N8e8a06be1c8a44d5a6e31e700f6197a2
    9 N973fa47805d14487ae21f1b7b7bc80a5
    10 N9a9a80215ede4865ac161bace2f203f4
    11 Nb1d3978e275f4e9499261914e9aa00d3
    12 Ncdc41c4a40b54f0d8ef8898857d94de7
    13 Nde34fdd75e4d463da4e93453b4a85cff
    14 anzsrc-for:11
    15 anzsrc-for:1103
    16 schema:author Nef98623611fb4aff8d5b5affb579a1e4
    17 schema:citation sg:pub.10.1038/clpt.1981.154
    18 schema:datePublished 2012-08-09
    19 schema:datePublishedReg 2012-08-09
    20 schema:description Case The objective of this case report is to report the development of tardive dyskinesia in an African-American adolescent male after short-term treatment with metoclopramide 10 mg orally three times daily secondary to delayed gastric emptying. The patient developed symptoms of tardive dyskinesia after 2 days of therapy with metoclopramide. Metoclopramide was discontinued and diphenhydramine 50 mg was initially administered intravenously followed with 25 mg orally every 4 hours as needed. While there are case reports of drug-induced tardive dyskinesia after intravenous administration of metoclopramide, this is to our knowledge the first report of tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent. Conclusion Awareness of the risk of development of this adverse effect even with short-term treatment with metoclopramide and in younger patients is important.
    21 schema:genre article
    22 schema:inLanguage en
    23 schema:isAccessibleForFree false
    24 schema:isPartOf Nd47214e58aeb445496989193b959bba8
    25 Ne98397cdf750446f81b93fe5e83841b6
    26 sg:journal.1044817
    27 schema:keywords African American adolescent males
    28 Conclusion Awareness
    29 administration
    30 adolescent males
    31 adolescents
    32 adverse effects
    33 awareness
    34 case report
    35 cases
    36 days
    37 days of therapy
    38 development
    39 effect
    40 first report
    41 hours
    42 intravenous administration
    43 knowledge
    44 males
    45 metoclopramide
    46 metoclopramide 10
    47 objective
    48 oral metoclopramide
    49 patients
    50 report
    51 risk
    52 risk of development
    53 short-term treatment
    54 symptoms
    55 therapy
    56 time
    57 treatment
    58 younger patients
    59 schema:name Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent
    60 schema:pagination 822-824
    61 schema:productId N14aec87662ed48e692a6159b1177e0f4
    62 N25d303358c7c42fe91c96d6f8fc1188c
    63 Na22aac76c9c94e8788325499741d89a6
    64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024100946
    65 https://doi.org/10.1007/s11096-012-9685-4
    66 schema:sdDatePublished 2021-12-01T19:26
    67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    68 schema:sdPublisher N57f25118d39644598f6f9b78c4f69803
    69 schema:url https://doi.org/10.1007/s11096-012-9685-4
    70 sgo:license sg:explorer/license/
    71 sgo:sdDataset articles
    72 rdf:type schema:ScholarlyArticle
    73 N14aec87662ed48e692a6159b1177e0f4 schema:name dimensions_id
    74 schema:value pub.1024100946
    75 rdf:type schema:PropertyValue
    76 N25d303358c7c42fe91c96d6f8fc1188c schema:name doi
    77 schema:value 10.1007/s11096-012-9685-4
    78 rdf:type schema:PropertyValue
    79 N3e5ec56a2589450dbd4b4fb1c8ddc5b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    80 schema:name Male
    81 rdf:type schema:DefinedTerm
    82 N482bed2db8e4480aa6b5610b1faa9b33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    83 schema:name Risk Factors
    84 rdf:type schema:DefinedTerm
    85 N4c92672c59e34e559b79a764fa28a5e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    86 schema:name Administration, Oral
    87 rdf:type schema:DefinedTerm
    88 N57f25118d39644598f6f9b78c4f69803 schema:name Springer Nature - SN SciGraph project
    89 rdf:type schema:Organization
    90 N5af07f013f3d4f54901e3867fa934a76 rdf:first sg:person.0715544021.50
    91 rdf:rest rdf:nil
    92 N5bdb298e89804acd98d4ba11098c4b05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    93 schema:name Diphenhydramine
    94 rdf:type schema:DefinedTerm
    95 N640a0d24afc74a248d850eb39e459318 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    96 schema:name Antiemetics
    97 rdf:type schema:DefinedTerm
    98 N65397430d53f479480831050017bd91d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    99 schema:name Drug Substitution
    100 rdf:type schema:DefinedTerm
    101 N71ee21f9499a4f29b16cee2a4bfed5a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    102 schema:name Age Factors
    103 rdf:type schema:DefinedTerm
    104 N8e8a06be1c8a44d5a6e31e700f6197a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    105 schema:name Adolescent
    106 rdf:type schema:DefinedTerm
    107 N973fa47805d14487ae21f1b7b7bc80a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    108 schema:name Time Factors
    109 rdf:type schema:DefinedTerm
    110 N9a9a80215ede4865ac161bace2f203f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Movement Disorders
    112 rdf:type schema:DefinedTerm
    113 Na22aac76c9c94e8788325499741d89a6 schema:name pubmed_id
    114 schema:value 22875741
    115 rdf:type schema:PropertyValue
    116 Nb1d3978e275f4e9499261914e9aa00d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Metoclopramide
    118 rdf:type schema:DefinedTerm
    119 Ncdc41c4a40b54f0d8ef8898857d94de7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Humans
    121 rdf:type schema:DefinedTerm
    122 Nd47214e58aeb445496989193b959bba8 schema:issueNumber 6
    123 rdf:type schema:PublicationIssue
    124 Ndc02d0bc18da4111b8cc1ecc662d36f6 rdf:first sg:person.0601042140.08
    125 rdf:rest N5af07f013f3d4f54901e3867fa934a76
    126 Nde34fdd75e4d463da4e93453b4a85cff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Drug Administration Schedule
    128 rdf:type schema:DefinedTerm
    129 Ne7124125060c464482b9a87c8dbe80e4 schema:affiliation grid-institutes:grid.267301.1
    130 schema:familyName Karimi Khaledi
    131 schema:givenName Maryam
    132 rdf:type schema:Person
    133 Ne98397cdf750446f81b93fe5e83841b6 schema:volumeNumber 34
    134 rdf:type schema:PublicationVolume
    135 Nef98623611fb4aff8d5b5affb579a1e4 rdf:first Ne7124125060c464482b9a87c8dbe80e4
    136 rdf:rest Ndc02d0bc18da4111b8cc1ecc662d36f6
    137 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    138 schema:name Medical and Health Sciences
    139 rdf:type schema:DefinedTerm
    140 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    141 schema:name Clinical Sciences
    142 rdf:type schema:DefinedTerm
    143 sg:journal.1044817 schema:issn 2210-7703
    144 2210-7711
    145 schema:name International Journal of Clinical Pharmacy
    146 schema:publisher Springer Nature
    147 rdf:type schema:Periodical
    148 sg:person.0601042140.08 schema:affiliation grid-institutes:grid.267301.1
    149 schema:familyName Suda
    150 schema:givenName Katie J.
    151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601042140.08
    152 rdf:type schema:Person
    153 sg:person.0715544021.50 schema:affiliation grid-institutes:grid.267301.1
    154 schema:familyName Shelton
    155 schema:givenName Chasity M.
    156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715544021.50
    157 rdf:type schema:Person
    158 sg:pub.10.1038/clpt.1981.154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040267576
    159 https://doi.org/10.1038/clpt.1981.154
    160 rdf:type schema:CreativeWork
    161 grid-institutes:grid.267301.1 schema:alternateName Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 340, 38163, Memphis, TN, USA
    162 Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 343, 38163, Memphis, TN, USA
    163 schema:name Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 340, 38163, Memphis, TN, USA
    164 Department of Clinical Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Suite 343, 38163, Memphis, TN, USA
    165 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...